The CAMPATH-1antigen (CDw52). Tissue Antigens 1990; 35:118–27. , , , , .
CD52 (Campath-1). J Biol Regul Homeost Agents 2001; 15:386–91. .
et al. Expression of human CD52 in human hematopoietic malignancies. Blood 1998; 92: Abstract 4199. , ,
Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils. Blood 1996; 88:4684–93. , , , .
Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood 1993; 82:807–12. , .
Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res 2006; 12:7174–9. , , , , , , , .
et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res 1998; 22:185–91. , ,
CD52 antigen – a review. Med Sci Monit 2001; 7:325–31. , .
Cross-linking of the Campath-1 antigen (CD52) triggers activation of normal human T lymphocytes. Int Immunol 1995; 7:69–77. , , , .
et al. Characterization of the 4C8 antigen involved in transendothelial migration of CD26hi T cells after tight adhesion to human umbilical vein endothelial cell monolayers. J Exp Med 1999; 189:979–89. , ,
et al. CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells. Clin Immunol 2006; 120:247–59. , ,
et al. Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab. Leuk Res 2008; 32:1849–56. , ,
Effect of alemtuzumab on neoplastic B cells. Haematologica 2004; 89:1476–83. , , , .
et al. CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity (CMC) but not antibody-dependent cellular cytotoxicity (ADCC): Pre-clinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin’s lymphoma (NHL). Leuk Lymphoma 2007; 48:2424–36. , ,
Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Immunology 1998; 95:427–36. , , , .
Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells. Leuk Lymphoma 2005; 46:87–100. , , , , , , .
et al. Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism. Leukemia 2006; 20:272–9. , ,
A review of Campath in autoimmune disease: biologic therapy in the gray zone between immunosuppression and immunoablation. Hematology 2005; 10:79–93. .
Repopulation of blood lymphocyte sub-populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH-1H. Immunology 1996; 88:13–19. , , , , , .
et al. The window of therapeutic opportunity in multiple sclerosis. Evidence from monoclonal antibody therapy. J Neurol 2006; 253:98–108. , ,
Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol 2005; 35:3332–42. , , , , , , , .
Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008; 359:1786–801. , , , , , , , .
Transient immunosuppression with deoxyspergualin improves longevity of transgene expression and ability to readminister adenoviral vector to the mouse lung. Hum Gene Ther 1997; 8:1095–104. , .
Importance of antigen specificity for complement-mediated lysis by monoclonal antibodies. Eur J Immunol 1988; 18:1507–14. , , .
et al. Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Blood 2002; 100:1715–20. , ,
Rationale for cytotoxic monoclonal antibodies in MS. Int MS J 2007; 14:48–56. , .
et al. Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia. Arthritis Rheum 2001; 44:1998–2008. , ,
et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1995; 354:1691–5. , ,
Different mechanisms of Campath-1H-mediated depletion for CD4+ and CD8+ T cells in peripheral blood. Transpl Int 2006; 19:927–36. , , , .
et al. Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest 1996; 98:2819–26. , ,
Neutrophils contribute to the biological antitumor activity of Rituximab in a non-Hodgkin’s lymphoma severe combined immunodeficiency mouse model. Clin Cancer Res 2003; 9:5866–73. , , , , , , .
Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model. Leuk Lymphoma 2005; 46:1775–84. , , , , .